Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4

Cancer Research

Volumn 66, Issue 11, 2006, Pages 5624-5632

  Ho, Shuk Mei ^a   Tang, Wan Yee ^a   Belmonte De Frausto, Jessica ^b   Prins, Gail S ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; CYCLIC AMP; ENDOCRINE DISRUPTOR; ENZYME VARIANT; ESTRADIOL; MOLECULAR MARKER; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV D4; UNCLASSIFIED DRUG;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; ENVIRONMENTAL EXPOSURE; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HORMONAL CARCINOGENESIS; MALE; NEWBORN; NONHUMAN; PRECANCER; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROSTATE CANCER; RAT;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; ANIMALS, NEWBORN; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIGENESIS, GENETIC; ESTRADIOL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOMIC IMPRINTING; ISOENZYMES; MALE; PHENOLS; PRECANCEROUS CONDITIONS; PREGNANCY; PROSTATE; PROSTATIC NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33745246032     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0516     Document Type: Article

References (50)

1. Colborn T. Environmental estrogens: health implications for humans and wildlife. Environ Health Perspect 1995;103:135-6.
2. Dodds EC, Lawson W. Synthetic estrogenic agents without phenanthrene nucleus. Nature 1936;137:996-7.
3. Krishnan AV, Stathis P, Permuth SF, Tokes L, Feldman D. Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving. Endocrinology 1993;132:2279-86.
4. Quesada I, Fuentes E, Viso-Leon MC, Ripoll C, Nadal A. Low doses of the endocrine disrupter bisphenol-A and the native hormone 17β-estradiol rapidly activate the transcription factor CREB. FASEB J 2002;16:1671-3.
5. Schonfelder G, Wittfoht W, Hopp H, Talsness CE, Paul M, Chahoud I. Parent bisphenol A accumulation in the human maternal-fetal-placental unit. Environ Health Perspect 2002;110:A703-7.
6. Howdeshell KL, Hotchkiss AK, Thayer KA, Vandenbergh JG, vom Saal FS. Environmental toxins: exposure to bisphenol A advances puberty. Nature 1999;401:763-4.
7. Markey CM, Wadia PR, Rubin BS, Sonnenschein C, Soto AM. Long-term effects of fetal exposure to low doses of the xenoestrogen bisphenol-A in the female mouse genital tract. Biol Reprod 2005;72:1344-51.
8. Henderson BH, Bernstein L, Ross RK, Depuc RH. Judd HL. The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br J Cancer 1988;57:216-8.
9. Powell IJ, Meyskens FL, Jr. African American men and hereditary/familial prostate cancer: intermediate-risk populations for ehenioprevention trials. Urology 2001;57:178-81.
10. Rajfer J, Coffey DS. Effects of neonatal steroids on male sex tissues. Invest Urol 1979;17:3-8.
11. Prins GS. Neonatal estrogen exposure induces lobe-specific alterations in adult rat prostate androgen receptor expression. Endocrinology 1992;130:3703-14.
12. Huang L, Pu Y, Alam S, Birch L, Prins GS. Estrogenic regulation of signaling pathways and homeobox genes during rat prostate development. J Androl 2004;25:330-7.
13. Prins GS. Developmental estrogenization of the prostate gland. In: Naz RK, editor. Prostate: basic and clinical aspects. Chapter 10. Boca Raton: CRC Press; 1997. p. 247-65.
14. vom Saal FS, Timms BG, Montano MM, et al. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc Natl Acad Sci USA 1997;94:2056-61.
15. Newbold RR, Jefferson WN, Padilla-Banks E, Haseman J. Developmental exposure to diethylstilbestrol (DES) alters uterine response to estrogens in prepuhescent mice: low versus high dose effects. Reprod Toxicol 2004;18:399-406.
16. Munoz-de-Toro M, Markey CM, Wadia PR, et al. Perinatal exposure to bisphenol-A alters peripubertal mammary gland development in mice. Endocrinology 2005;146:4138-47.
17. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26:833-76.
18. Modugno F, Weissfeld JL, Trump DL, et al. Allelic variants of aromatase and androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 2001;7:3092-6.
19. Leav I, Ho S, Ofner P, Merk F, Kwan P, Damassa D. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J Natl Cancer Inst 1988;80:1045-53.
20. Momparler R, Bovenzi V. DNA methylation and cancer. J Cell Physiol 2000;183:145-54.
21. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 2005;45:629-56.
22. Lyn-Cook BD, Blann E, Payne PW, Bo J, Sheehan D, Medlock K. Methylation profile and amplification of proto-oncogen es in rut pancreas induced with phytoestrogens. Proc Soc Exp Biol Med 1995;208:116-9.
23. Li S, Washburn KA, Moore R, et al. Developmental exposure to diethylstilbestrol elicits dcmethylation of estrogen-responsive lactorferrin gene in mouse uterus. Cancer Res 1997;57:4356-9.
24. Alworth LC, Howdeshell KL, Ruhlen RL, et at. Uterine responsiveness to estradiol and DNA methylation are altered by fetal exposure to diethylstilbestrol and methoxychlor in CD-1 mice: effects of low versus high doses. Toxicol Appl Pharmacol 2002;183:10-22.
25. Anway MD, Cupp AS, Uzumcu M, Skinner MK. Epigenetic transgenerational actions of endocrine disuptors and male fertility. Science 2005;308:1466-9.
26. Putz O, Schwartz CB, Kim S, LeBlanc GA, Cooper RL, Prins GS. Neonatal low- and high-dose exposure to estradiol benzoate in the male rat. I. Effects on the prostate gland. Biol Reprod 2001;65:1496-505.
27. Nagel SC, vom Saal FS, Thayer KA, Dhar MG, Boechler M, Weshons WV. Relative binding affinity-serum modified access (RBA-SMA) assay predicts the relative in vivo bioactivity of the xenoestrogens bisphenol A and octylphenol. Environ Health Perspect 1997;105:70-6.
28. Lee C, Prins GS, Henneberry MO, Grayhack JT. Effect of estradiol on the rat prostate in the presence and absence of testosterone and pituitary. J Androl 1981;2:293-9.
29. Yu M, Cates J, Leav I, Ho S. Heterogeneity of [3H]estradiol binding sites in the rat prostate: properties and distribution of type I and type II sites. J Steroid Biochem 1989;33:449-57.
30. Bosland MC, Ford H, Horton L. Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol- 17β or dietlhylstilbestrol. Carcinogenesis 1995;16:1311-7.
31. Shappell S, Thomas D, Roberts R, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Biology Committee. Cancer Res 2004;64:2270-305.
32. Huang TH, Laux DE, Hamlin BC, Tran P, Tran H, Lubahn DB. Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique. Cancer Res 1997;57:1030-4.
33. Li LC, Dahiva R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002;18:1427-31.
34. Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T. BiQ Analyzer: visualization and quality control for DNA methylation data from bisulphite sequencing. Bioinformatics 2005;21:4067-8.
35. Lau KM, LaSprina M, Iong J, Ho SM. Expression of estrogen receptor (ER)-α and ER-β in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 2000;60:702-6.
36. Chang SM, Chung LW. Interaction between prostatic fihroblast and epithelial cells in culture: rule of androgen. Endocrinology 1989;125:2719-27.
37. Newbold KR, Bullock BC, McLachlan JA. Uterine adenocarcinoma in mice following developmental treatment with estrogens: a model for hormonal carcinogenesis. Cancer Res 1990;50:7677-81.
38. Shihala A, Minn AY. Perinatal sex hormones and risk of breast and prostate cancers in adulthood. Epidemiol Rev 2000;22:239-48.
39. Birnbaum LS, Fenton SE. Cancer and developmental exposure to endocrine disruptors. Environ Health Perspect 2003;111:389-94.
40. Baik I, Devito WJ, Ballen K, et al. Association of fetal hormone levels with stem cell potential: evidence for early life roots of human cancer. Cancer Res 2005;65:358-63.
41. Wetherill YB, Petre CE, Monk KR, Puga A, Knudsen KE. The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. Mol Cancer Ther 2002;1:515-24.
42. Greco T, Duello T, Gorski J. Estrogen receptors, estradiol, and diethylstilbestrol in early development: the mouse as a model for the study of estrogen receptors and estrogen sensitivity in embryonic development of male and female reproductive tracts. Endocr Rev 1993;14:59-71.
43. McLachlan JA. Environmental signaling: what embryos and evolution teach us about endocrine disrupting chemicals. Endocr Rev 2001;22:319-41.
44. Conti M, Swimnen JV. Structure and function of the rolipram-sensitive, low-Km cyclic AMP phosphodiesterase: a family of highly related enzymes. In: Houslay MD, Beavo JA, editors. Molecular pharmacology of cell regulation: cyclic nucleotide phosphodiesterase structure, regulation, and drug action. New York: Wiley; 1990. p. 243-66.
45. Fimia GM, Sassone-Corsi P. Cyclic AMP signalling. J Cell Sci 2001;114:1971-2.
46. Jin S-LC, Bushnik T, Lan L, Conti M. Subcellular localization of rolipram-sensitive, cAMP-specific phosphodiesterases. J Biol Chem 1998;273:19672-8.
47. Chen TC, Wadsten P, Su S, et al. The type IV phosphodiesterase inhibitor rnlipram induces expression of the cell cycle inhibitiors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells. Cancer Biol Ther 2002;1:268-76.
48. Narita M, Murata T, Shimizu K, et al. Phosphodiesterase 4 in osteoblastic osteosarcoma cells as a potential target for growth inhibition. Anticancer Drugs 2003;14:377-81.
49. Lerner A, Kim DH, Lee R. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies. Leuk Lymphoma 2000;37:39-51.
50. Hirsh L, Dantes A, Suh B-S, et al. Phosphodiesterase inhibitors as anti-cancer drugs. Biochem Pharmacol 2004;68:981-8.